<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702920</url>
  </required_header>
  <id_info>
    <org_study_id>IG1407</org_study_id>
    <nct_id>NCT03702920</nct_id>
  </id_info>
  <brief_title>Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%</brief_title>
  <acronym>APACHE</acronym>
  <official_title>Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With &quot;Acute-On-Chronic Liver Failure&quot; (ACLF) at High Risk of Hospital Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to&#xD;
      evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in&#xD;
      acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study&#xD;
      centers in the United States, Canada, and Europe with expertise in the management of subjects&#xD;
      with ACLF.&#xD;
&#xD;
      Subjects with ACLF at a high risk of hospital mortality will be enrolled. The study will&#xD;
      consist of a Screening Period during which subjects will be randomized (1:1) to receive&#xD;
      either standard medical treatment (SMT) + PE-A 5% (treatment group) or SMT only (control&#xD;
      group), followed by a Treatment Period, and a Follow-up Period.&#xD;
&#xD;
      The Treatment Period for subjects in the SMT+ PE-A 5% treatment group will be between 7 and&#xD;
      17 days, depending on ACLF evolution.&#xD;
&#xD;
      The Treatment Period for subjects in the SMT control group will be a minimum of 7 days for&#xD;
      all subjects and up to 17 days depending on the ACLF evolution. Subjects in this group will&#xD;
      receive SMT according to the institution's standards.&#xD;
&#xD;
      The Follow-up Period for subjects in both groups will be 90 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 380 subjects with cirrhosis, ACLF, and high risk of hospital mortality&#xD;
      (ACLF-1b, ACLF-2, or ACLF-3a) will be included in this study after obtaining written informed&#xD;
      consent. In case of hepatic encephalopathy (HE), written informed consent will be obtained&#xD;
      from a relative or a legally authorized representative (surrogate).&#xD;
&#xD;
      Randomization of subjects will be stratified by region (European Union [EU] or North America&#xD;
      [NA]) and the 3 ACLF grades (ACLF-1b, ACLF-2, or ACLF-3a). Within each stratum (ie, each&#xD;
      unique combination of region and ACLF grade), subjects will be randomized in a 1:1 ratio into&#xD;
      2 treatment groups below:&#xD;
&#xD;
        -  SMT+PE-A 5% (treatment group)&#xD;
&#xD;
        -  SMT (control group)&#xD;
&#xD;
      SMT + PE-A 5% Treatment Group:&#xD;
&#xD;
      PE-A 5% will be performed using 5% albumin (Albutein® 5%) as the main replacement fluid&#xD;
      administered intravenously. Fresh frozen plasma (FFP) will be given after each PE-A 5%&#xD;
      session to prevent coagulopathy.&#xD;
&#xD;
      The exact number of sessions will be determined by the pattern of response (achieving&#xD;
      complete response or no improvement/deterioration of ACLF) to PE-A 5% therapy. IVIGs will be&#xD;
      administered to prevent the development of hypogammaglobulinemia and infection.&#xD;
&#xD;
      SMT Control Group:&#xD;
&#xD;
      The Treatment Period will be 7 days for all subjects and will be prolonged depending on&#xD;
      subject's ACLF evolution to up to 17 days.&#xD;
&#xD;
      Subjects in both the SMT+ PE-A 5% treatment group and the SMT control group will be followed&#xD;
      for 90 days after randomization. During the entire study, the safety of both groups will be&#xD;
      monitored by a Data Safety Monitoring Board.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death through Day 90</measure>
    <time_frame>Day 1 to Day 90</time_frame>
    <description>Time to death through Day 90 after randomization of SMT+PE-A 5% versus SMT alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to transplant or death through Day 90</measure>
    <time_frame>Day 1 to Day 90</time_frame>
    <description>Time to transplant or death through Day 90 after randomization of SMT+PE-A 5% versus SMT alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death through Day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to death through Day 28 after randomization of SMT+PE-A 5% versus SMT alone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>SMT+ PE-A 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment (SMT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard medical treatment (SMT) will be administered according to institution standards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SMT + PE-A 5%</intervention_name>
    <description>Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.</description>
    <arm_group_label>SMT+ PE-A 5%</arm_group_label>
    <other_name>Albutein 5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Standard medical treatment according to the institution's standard practice</description>
    <arm_group_label>Standard Medical Treatment (SMT)</arm_group_label>
    <other_name>SMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female cirrhotic subjects between 18 and 79 years of age.&#xD;
&#xD;
          -  Subjects with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during&#xD;
             hospitalization (must be ACLF-1b, -2, or -3a within the Screening Period [a maximum of&#xD;
             10 days]).&#xD;
&#xD;
          -  Willing and able to provide written informed consent or have an authorized&#xD;
             representative able to provide written informed consent on behalf of the subject in&#xD;
             accordance with local law and institutional policy.&#xD;
&#xD;
          -  In case of HE, informed consent will be provided by a relative or a legally authorized&#xD;
             representative (surrogate).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects without ACLF.&#xD;
&#xD;
          -  Subjects with ACLF-1a or ACLF-3b (See Table 2-1 for ACLF grades) after the Screening&#xD;
             Period.&#xD;
&#xD;
          -  Subjects fulfilling inclusion criteria that improve to no ACLF or to ACLF-1a or worsen&#xD;
             to ACLF-3b during the Screening Period (between initial evaluation and time of&#xD;
             randomization).&#xD;
&#xD;
          -  Subjects with ACLF for more than 10 days prior to randomization.&#xD;
&#xD;
          -  Subjects with acute or subacute liver failure without underlying cirrhosis.&#xD;
&#xD;
          -  Subjects with septic shock requiring use of norepinephrine (&gt; 0.3 mcg/kg/min) or need&#xD;
             for a second vasopressor (including terlipressin).&#xD;
&#xD;
          -  Subjects with active bacterial or fungal infection: who have received less than 24h of&#xD;
             appropriate antibiotic treatment.&#xD;
&#xD;
          -  Subjects with severe respiratory failure with PaO2/FiO2 ≤200.&#xD;
&#xD;
          -  Subjects with active or recent bleeding (unless controlled for &gt;48 hours).&#xD;
&#xD;
          -  Subjects with severe thrombocytopenia (≤20×109/L) (based on local laboratory&#xD;
             assessment).&#xD;
&#xD;
          -  Subjects with chronic renal failure and currently receiving hemodialysis.&#xD;
&#xD;
          -  Evidence of current locally advanced or metastatic malignancy. Subjects with&#xD;
             hepatocellular carcinoma within the Milan criteria (1 nodule ≤5 cm or 3 nodules ≤3 cm&#xD;
             [Appendix 5]), non-melanocytic skin cancer, and controlled breast or prostate cancer,&#xD;
             can be included).&#xD;
&#xD;
          -  Subjects with severe chronic heart failure (New York Heart Association [NYHA] class&#xD;
             III or IV).&#xD;
&#xD;
          -  Subjects with severe pulmonary disease (Global Obstructive Lung Disease [GOLD] stage&#xD;
             III or IV).&#xD;
&#xD;
          -  Subjects with severe myopathy as defined clinically.&#xD;
&#xD;
          -  Subjects with a known infection with human immunodeficiency virus (HIV) or have&#xD;
             clinical signs and symptoms consistent with current HIV infection.&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding, or if of childbearing potential, unwilling to&#xD;
             practice a highly effective method of contraception.&#xD;
&#xD;
          -  Subjects with previous liver transplantation.&#xD;
&#xD;
          -  Subjects receiving anti-platelet or anti-coagulant therapy (LMWH for DVT prophylaxis&#xD;
             is allowed).&#xD;
&#xD;
          -  Participation in another clinical study within at least 30 days prior to screening.&#xD;
&#xD;
          -  Subjects with active drug addiction (exceptions: active alcoholism or marijuana).&#xD;
&#xD;
          -  Subjects with a do-not-resuscitate order.&#xD;
&#xD;
          -  In the opinion of the investigator, the subject may have compliance problems with the&#xD;
             protocol and the procedures of the protocol.&#xD;
&#xD;
          -  Subjects with current infection of COVID19, those who are less than 14 days post&#xD;
             recovery or those who have clinical signs and symptoms consistent with COVID19&#xD;
             infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mireia Torres</last_name>
    <phone>+34 93 5710500</phone>
    <email>approach_apache@grifols.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB) Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan McGuire</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo E. Vargas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay Sundaram</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ram Subramanian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jody Olson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers-New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Raval</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Simonetto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Rajender Reddy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Al- Khafaji</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmohan Bajaj</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kramer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Reiberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Gustot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Wilmer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fin Stolze Larsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhael Giabicani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-Biliaire - Hôpital Universitaire Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faouzi Saliba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonel Trebicka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Maasoumy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Berg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Steib</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Perricone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milano Hospital Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Iavarone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Angeli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Merli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nery Filipe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario del Valle Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Vargas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Fernández</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Bañares</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free NHS Foundation Trust Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautam Mehta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Bernal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

